| | | 占用方与上市公司 | 上市公司核算的会 | 2023 | 年期初 | 2023 年度占 用累计发生 | 2023 年度 占用资金 | 2023 | 年度偿还 | 2023 年期末 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | | | | | | | | 占用资金余 | | 占用性质 | | | | 的关联关系 | 计科目 | | 占用资金余额 | 金额 | 的利息 | | 累计发生金额 | 额 | 成原因 | | | | | | | | | （不含利息） | （如有） | | | | | | | | | | | | | | | | | | | 非经营性占 | | 控股股东、实际控制人及其 | | | | | | | | | | | | 用 | | 附属企业 | | | | | | | | | | | | 非经营性占 | | | | | | | | | | | | | | 用 | | 小 计 | - | - | - | ...

湖南达嘉维康医药产业股份有限公司 2023 年度审计报告 | | | | 一、审计报告……………………………………………………… | | 第 1—5 | | 页 | | --- | --- | --- | --- | --- | | 二、财务报表……………………………………………………… | 第 | 6—13 | | 页 | | （一）合并资产负债表…………………………………………… | | 第 6 | | 页 | | （二）母公司资产负债表………………………………………… | | 第 7 | | 页 | | （三）合并利润表………………………………………………… | | 第 | 8 | 页 | | （四）母公司利润表……………………………………………… | | 第 | 9 | 页 | | （五）合并现金流量表……………………………………………第 | | | 10 | 页 | | （六）母公司现金流量表…………………………………………第 | | | 11 | 页 | | （七）合并所有者权益变动表……………………………………第 | | | 12 | 页 | | （八）母公司所有者权益变动表………………………… ...

Financial Performance - The company's revenue for Q1 2024 reached ¥1,280,469,171.09, representing a 46.06% increase compared to ¥876,697,159.06 in the same period last year[6] - Net profit attributable to shareholders was ¥19,436,945.89, up 27.14% from ¥15,287,632.67 year-on-year[6] - Net profit for Q1 2024 was ¥22,059,938.81, representing a 16% increase from ¥18,898,654.75 in Q1 2023[31] - Total operating revenue for Q1 2024 reached ¥1,280,469,171.09, a significant increase of 46% compared to ¥876,697,159.06 in the same period last year[29] - Total operating costs for Q1 2024 were ¥1,248,476,553.31, which is a 48% increase from ¥843,561,238.37 in Q1 2023[29] - The company reported a basic earnings per share of ¥0.09, compared to ¥0.07 in the same quarter last year, indicating a 28.6% increase[32] Cash Flow and Liquidity - The net cash flow from operating activities was -¥175,488,409.39, a decline of 87.40% compared to -¥93,644,192.00 in the previous year[6] - Cash flow from operating activities showed a net outflow of ¥175,488,409.39, worsening from a net outflow of ¥93,644,192.00 in Q1 2023[34] - The company's cash and cash equivalents decreased to RMB 392,530,769.23 from RMB 649,399,091.38, reflecting a decline of about 39.5%[24] - The ending balance of cash and cash equivalents was 354,815,404.93 CNY, down from 437,643,887.18 CNY year-over-year, indicating a decrease in liquidity[37] - The initial cash and cash equivalents balance was 617,317,750.46 CNY, compared to 520,743,935.35 CNY in the previous year, indicating a stronger starting liquidity position[37] Assets and Liabilities - Total assets increased by 14.59% to ¥6,047,540,005.59 from ¥5,277,655,319.75 at the end of the previous year[6] - The company's total liabilities increased to ¥4,214,968,157.10, up from ¥3,496,005,825.13, marking a growth of approximately 20.5% year-over-year[28] - The total current liabilities increased, with accounts payable rising to RMB 531,504,320.55 from RMB 402,725,045.60, an increase of about 32%[26] - Short-term borrowings rose by 9.87% to ¥1,671,646,157.03, driven by loans related to recent acquisitions[11] - The company's long-term borrowings increased to ¥1,133,800,123.89, up from ¥833,747,035.01, representing a growth of approximately 36%[28] Investments and Research - Research and development expenses surged by 186.31% to ¥2,061,921.04, primarily due to follow-up investments in newly acquired units[12] - Research and development expenses rose to ¥2,061,921.04, which is a 186% increase compared to ¥720,168.56 in the previous year[29] - The company experienced a 120.39% increase in net cash flow from investing activities, amounting to -¥425,988,313.13, attributed to investments in equity of other companies[14] - Cash paid for investment activities totaled 426,013,308.13 CNY, significantly higher than 209,292,390.70 CNY in the prior year, indicating aggressive investment strategies[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,430[16] - The company plans to issue 1.26 million shares of restricted stock and 2.94 million stock options to 33 incentive targets as part of its employee incentive program[21] - The company has approved a proposal for a specific stock issuance plan for 2024, which is expected to enhance its capital structure and support future growth initiatives[22] - The company has not reported any changes in the number of restricted shares for major shareholders during the period[19] Goodwill and Inventory - The goodwill on the balance sheet increased significantly to RMB 1,052,835,774.91 from RMB 717,930,711.43, reflecting a rise of approximately 46.6%[26] - The company reported a significant increase in inventory by 33.51% to ¥839,927,786.20 due to newly acquired enterprises[11] - Inventory rose to RMB 839,927,786.20 from RMB 629,106,306.73, indicating a growth of around 33.4%[26] - Accounts receivable increased to RMB 1,711,137,728.19 from RMB 1,565,646,271.02, marking an increase of approximately 9.3%[25] Financing Activities - Total cash inflow from financing activities was 741,000,000.00 CNY, up from 449,951,126.73 CNY year-over-year, reflecting a strong financing position[36] - The net cash flow from financing activities was 338,974,376.99 CNY, compared to 203,836,534.53 CNY in the same period last year, showing improved cash generation from financing[36] - The company received 720,000,000.00 CNY in borrowings during the quarter, compared to 398,000,000.00 CNY in the previous year, highlighting increased leverage[36] - Cash received from sales of goods and services was ¥1,188,214,685.67, an increase of 45% from ¥816,248,755.94 in the previous year[34] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[38]

国金证券股份有限公司 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为湖南 达嘉维康医药产业股份有限公司（以下简称"达嘉维康"或"公司"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，对达嘉维康《2023 年度 内部控制评价报告》进行了核查，核查情况如下： 一、达嘉维康内部控制评价工作情况 关于湖南达嘉维康医药产业股份有限公司 2023 年度内部控制评价报告的核查意见 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 1、纳入评价范围的主要单位包括： 湖南达嘉维康医药产业股份有限公司以及合并报表范围内的子公司。 2、纳入评价范围的单位占比： | 指标 | 占比 | | --- | --- | | | （%） | | 纳入评价范围单位的资产总额占公司合并财务报表资产总额之比 | 100 | | 纳入评价范围单位的营业收入合计占公司合并财务报表营业收入总额之比 | 100 | 3、纳入评价范 ...

一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 证券代码：301126 证券简称：达嘉维康 公告编号：2024- 040 湖南达嘉维康医药产业股份有限公司 2023 年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》和《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关规定，经湖南达嘉维康医药产业股份有限 公司（以下简称"公司"、"本公司"）第四届董事会第七次会议通过，公司编 制的《2023 年度募集资金存放与使用情况专项报告》如下： 根据中国证券监督管理委员会《关于同意湖南达嘉维康医药产业股份有限公 司首次公开发行股票注册的批复》（证监许可〔2021〕3367 号），本公司由主承 销商国金证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通 股（A 股）股票 51,626,425 股，发行价为每股人民币 12.37 元，共计募集资金 63,861.89 万元，坐扣承销费（不含 ...

国金证券股份有限公司 关于湖南达嘉维康医药产业股份有限公司 2023 年度定期现场检查报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有 关法律法规的要求，国金证券股份有限公司作为湖南达嘉维康医药产业股份有限 公司（以下简称"达嘉维康"或"公司"）持续督导之保荐机构，于 2024 年 4 月 18 日对达嘉维康有关情况进行了定期现场检查，报告如下： | 保荐人名称：国金证券股份有限公司 | 被保荐公司简称：达嘉维康 | | | | | | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：柳泰川 | 联系电话：021-68826801 | | | | | | 保荐代表人姓名：朱国民 | 联系电话：021-68826801 | | | | | | 现场检查人员姓名：朱国民 | | | | | | | 现场检查对应期间：2023 | 年度 | | | | | | 现场检查时间：2024 | 年 | 月 | 日 | 4 | 18 | | 一、现场检查事项 | 现场检查意见 | | | | | | （一）公司治理 | 是 | 否 | 不适用 | 现场 ...

湖南达嘉维康医药产业股份有限公司 2023 年度独立董事述职报告 （刘曙萍） 本人作为湖南达嘉维康医药产业股份有限公司（以下简称"公司"）的独立董事， 在 2023 年严格按照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创 业板股票上市规则》《公司章程》《独立董事工作制度》的规定，忠实、勤勉地履行了独 立董事的职责，谨慎、认真、恰当地行使了独立董事的职权，积极认真地出席了专门委 员会会议、董事会会议和股东大会，并充分发挥本人的经验和专长，在完善公司治理和 重大决策等方面做了许多工作，对有关事项发表了中肯、客观的意见，切实维护了公司 全体股东的利益。现将本人 2023 年度担任独立董事的履职情况报告如下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 本人刘曙萍，1970 年 1 月出生，中国国籍，无境外永久居留权，工商管理专业硕士。 2023 年 11 月至今上会会计师事务所（特殊普通合伙）湖南分所负责人；2013 年 10 月 至 2023 年 11 月，任大信会计师事务所(特殊普通合伙)长沙 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2024-046 湖南达嘉维康医药产业股份有限公司 关于召开 2023 年年度股东大会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合《中华人民 共和国公司法》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 5 月 14 日（星期二）14:30 （2）公司董事、监事及高级管理人员； （3）公司聘请的律师； （2）网络投票时间：2024 年 5 月 14 日（星期二） 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 14 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳交易所互联网投票系 统投票的具体时间为：2024 年 5 月 14 日 9:15—15:0 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2024- 036 湖南达嘉维康医药产业股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届监事会第六 次会议于 2024 年 4 月 20 日在公司会议室以现场结合通讯的方式召开。会议通知 已于 2024 年 4 月 10 日通过邮件的方式送达全体监事。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席唐娟女士召集并主持。本次会议 的召集、召开和表决程序符合《中华人民共和国公司法》等有关法律、法规及规 范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： （一）审议通过《关于<2023 年度监事会工作报告>的议案》 2023 年度，公司监事会按照《公司法》《证券法》等法律法规以及《公司章 程》《监事会议事规则》等有关规定的要求，对公司股东大会和董事会等会议的 召集召开程序、公司经营活动、财务状况、重大决策及董事、高级管理人 ...

Financial Performance - The company's operating revenue for 2023 reached ¥3,903,503,781.52, representing an increase of 18.56% compared to ¥3,292,323,125.82 in 2022[17]. - The net profit attributable to shareholders of the listed company decreased by 32.85% to ¥34,299,844.15 from ¥51,119,784.99 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥34,322,553.37, down 26.69% from ¥46,860,490.33 in 2022[17]. - The net cash flow from operating activities improved significantly to ¥27,130,076.95, a 105.49% increase from a negative cash flow of ¥493,964,014.75 in the previous year[17]. - The total assets of the company increased by 34.24% to ¥5,277,655,319.75 compared to ¥3,931,417,218.63 at the end of 2022[18]. - The net assets attributable to shareholders of the listed company rose by 1.45% to ¥1,747,230,887.13 from ¥1,723,242,970.64 at the end of 2022[18]. - The basic earnings per share decreased by 32.00% to ¥0.17 from ¥0.25 in the previous year[17]. - The diluted earnings per share also fell by 32.00% to ¥0.17 from ¥0.25 in 2022[17]. - The weighted average return on net assets was 1.98%, down from 3.01% in the previous year[18]. Dividend Distribution - The company plans to distribute a cash dividend of 0.4 RMB per 10 shares to all shareholders, based on a total of 206,505,700 shares[3]. - The cash dividend distribution represents 100% of the total profit distribution amount[178]. - The profit distribution plan includes a cash dividend of CNY 0.40 per 10 shares, totaling CNY 8,260,228.00 to be distributed to shareholders[182]. Market Trends and Growth - The total sales of the national pharmaceutical circulation market reached ¥275.16 billion in 2022, with a year-on-year growth of 6.0%[27]. - The number of retail pharmacies in China increased from 454,000 in 2017 to 623,300 in 2022, reflecting a growing market[33]. - The chain rate of retail pharmacies rose from 50.44% in 2017 to 57.76% in 2022, indicating increasing market concentration[33]. - The top 100 chain stores accounted for 49% of the revenue in 2022, up 3 percentage points from 2021, showing a trend towards market consolidation[33]. Revenue Breakdown - The distribution business generated revenue of CNY 2,301.14 million, accounting for 58.95% of total revenue, with a year-on-year growth of 1.11%[37]. - The retail business reported revenue of CNY 1,505.31 million, representing a significant increase of 51.53% compared to the previous year, and accounted for 38.56% of total revenue[41]. - The DTP specialty pharmacy sales reached CNY 832.48 million, a growth of 14.43% year-on-year, with 450 product varieties sold[40]. - The pharmaceutical industrial segment generated revenue of CNY 75.85 million, making up 1.94% of total revenue[42]. - The medical services segment, through the subsidiary Jiachen Hospital, reported revenue of CNY 12.77 million, a 35.12% increase year-on-year[43]. Acquisitions and Investments - The company completed the acquisition of Hunan Tianji Caotang Pharmaceutical Co., Ltd. for ¥398,003,400, achieving a 99.9899% ownership stake[82]. - The acquisition of Yinchuan Meihotai Pharmaceutical Chain Co., Ltd. was completed for ¥250,800,000, resulting in 100% ownership[82]. - The company is currently working on several major R&D projects, including the approval of Oseltamivir Phosphate Syrup, which is expected to enhance future performance if approved[64]. - The company is in the process of acquiring a 51% stake in Shanxi Simail Drug Chain Co., Ltd. for ¥326,001,022, which is yet to be completed[83]. Research and Development - Research and development expenses surged by 1,268.85% to CNY 7,173,235.40, attributed to follow-up investments in newly acquired enterprises[63]. - The R&D investment as a percentage of operating income was 0.18% in 2023, up from 0.02% in 2022[64]. - The number of R&D personnel decreased by 50% from 38 in 2022 to 19 in 2023, impacting the company's R&D capacity[64]. - The company plans to enhance its core competitiveness through the integration of R&D personnel from newly acquired production enterprises[65]. Corporate Governance - The governance structure complies with the requirements set by the China Securities Regulatory Commission[119]. - The board consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[122]. - The company has established a performance evaluation and incentive mechanism for its directors and senior management[124]. - The company strictly adheres to information disclosure obligations, ensuring equal access to information for all shareholders[125]. - The company actively manages investor relations through various communication channels[126]. Environmental Compliance - Hunan Tianji Caotang Pharmaceutical Co., Ltd. is listed as a key pollutant discharge unit for 2023, adhering to multiple environmental protection laws and standards[193]. - The company incurs an annual operational cost of 510,000 RMB for wastewater treatment and pays an environmental protection tax of 4,515.10 RMB for 2023[200]. - The company has implemented a comprehensive environmental monitoring plan, with various pollutants monitored semi-annually and annually[198]. - The company has no instances of exceeding pollutant discharge limits in its operations[196]. Employee Management - The total number of employees at the end of the reporting period was 3,461, including 548 at the parent company and 2,913 at major subsidiaries[168]. - The company has established a salary system based on a combination of ability and contribution, with performance pay directly linked to individual output[170]. - The company provides various employee benefits, including pension, medical, unemployment, work injury, maternity insurance, and housing fund[171]. - The company has implemented a training program to enhance employee skills and integrate new members into the company culture[172].